Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Neuroblastoma: The Way Ahead

22.06.2007
Future directions for treatment of the childhood cancer Neuroblastoma, and a detailed analysis of current regimens, are included in a Seminar in this week’s edition of The Lancet.

Plans for the development of an International Neuroblastoma Risk Group (INRG) classification system, to develop a consensus to permit comparisons of outcomes of neuroblastoma patients worldwide, are also included in the Seminar, authored by Dr John Maris, Children’s Hospital of Philadelphia, USA, and colleagues. The INRG is currently analysing data obtained from 11,054 patients treated in Europe, Japan, USA, Canada, and Australia between 1974 and 2002 so that this international classification system can be created.

Neuroblastoma is a cancer of the sympathetic nervous system - the nerve network that regulates the “fight or flight” response to the environment. When solid tumours form, which can take the form of a lump or mass, they commonly begin in one of the adrenal glands, though they can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

It is the most common solid extracranial cancer in childhood, and represents more than 7% of all childhood malignant cancers and 15% of all childhood cancer deaths. It is remarkable for its broad spectrum of clinical behaviour. Likelihood of cure varies widely according to age at diagnosis, extent of disease, and tumour biology.

The authors say: “Although substantial improvement in outcome of certain well-defined subsets of patients has been observed during the past few decades, the outcome for children with a high-risk clinical phenotype has improved only modestly, with long-term survival still less than 40%.”

There are three main sets of presenting signs and symptoms, categorised as localised tumours, metastatic disease, and 4S disease. Around 40% of patients present with localised tumours which can vary in size and occur anywhere in the sympathetic nervous system. In certain locations these tumours can cause compression of the spinal cord and resulting motor weakness in 5-15% of patients. Around half of patients present with metastatic disease, which often involves multiple tumour burdens which can make patients quite ill. This type of tumour can also metastatise bony orbits, and can lead to symptoms such as raccoon eyes (periorbital bruises). 4S disease occurs in only 5% of patients with neuroblastoma – and presents as small localised primary tumours with secondary tumours in liver, skin or bone marrow that almost always spontaneously regress.

The treatment methods used in neuroblastoma management include surgery, chemotherapy, radiotherapy, and biotherapy, as well as observation alone in carefully selected circumstances.

But new approaches to relapsed disease for patients with high-risk neuroblastoma have developed in recent years. These include cytotoxic agents, targeted delivery of radionuclides, immunotherapy, retinoids, angiogenesis inhibitors, and tyrosine kinase inhibitors.

The authors conclude that improvements in understanding of the genomic alterations associated with tumour and behaviour and patient outcome have moved the goal of precise prognosis closer.

They say: “Improved understanding of normal neurodevelopment of the sympathicoadrenal stem will help us identify the key mutational events that initiate neuroblastoma tumorigenesis. Defining these events, as well as those that reliably predict for the acquisition of a high-risk phenotype, might ultimately direct us to the key pathways that can be exploited therapeutically.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/Seminar.pdf

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>